Fused Heterocycle 5-HT2A Agonists With Reduced 5-HT2B Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing 5-HT2A receptor agonists lack selectivity over the 5-HT2B receptor, leading to potential toxicology issues such as drug-induced valvular heart disease.
Innovation Solution
Development of compounds that selectively bind to the 5-HT2A receptor over the 5-HT2B receptor, represented by specific fused heterocycles, which can be used in pharmaceutical compositions to treat neurological disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing 5-HT2A receptor agonists are used, then therapeutic effect is achieved, but selectivity over 5-HT2B receptor is poor leading to toxicology issues
Solution Approach 1:
The patent modifies molecular parameters of the agonist compounds by incorporating specific fused heterocyclic ring systems (such as pyrido[2,3-b]pyridine, pyrimido[4,5-b]pyridine, and other nitrogen-containing fused rings) at the 5-HT2A receptor binding site. These structural parameter changes enable selective binding to 5-HT2A over 5-HT2B, achieving the desired therapeutic effect while avoiding the toxicology issues associated with non-selective agonists.
2Reliability
If non-selective 5-HT2A/5-HT2B agonists are used, then therapeutic effect is achieved, but side effects increase
Solution Approach 1:
The patent introduces local quality differentiation by placing specific heterocyclic ring systems at the critical binding interface of the 5-HT2A receptor. The fused heterocyclic structures (such as those with nitrogen atoms at specific positions) create localized chemical features that are recognized preferentially by 5-HT2A over 5-HT2B, thereby achieving selective agonism and reducing side effects while maintaining therapeutic efficacy.
Data Source
AI summary
The disclosure provides compounds, e.g., compounds of Formula I, and their use in treating medical diseases or disorders, such as neurological disorders. Pharmaceutical compositions and methods of making various azaindole and benzisoxazole compounds are provided. The compounds are contemplated to be modulators of the 5-hydroxytryptamine 2A (5-HT2A) receptor.